Maxwell Biosciences today announced that they have entered into a second Cooperative Research and Development Agreement (CRADA) with the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID).
USAMRIID is the U.S Army’s premier institution and facility for defensive research into countermeasures against biological warfare, located on Fort Detrick, Maryland. USAMRIID will test Maxwell Biosciences‘ Claromer peptoids for use as an antiviral therapeutic agent in USAMRIID’s established in vivo infection models and as an antibacterial therapeutic against USAMRIID’s bacterial select agent collection.
Pending successful results from initial testing and by mutual agreement, small animal dosing and tolerability tests would also be performed by USAMRIID.
Maxwell Biosciences is a pre-clinical drug platform company that develops biomimetic therapeutics-synthetic compounds that mimic and improve upon natural immune system peptides. Inspired by nature, these small molecules have been shown to be effective against Ebola, pan-coronavirus, pan-Influenza A (avian, swine, and human) in destroying not just viruses, but also all tested bacteria, fungi and biofilms with a single compound, while safely avoiding healthy cells. This “One Drug for Many Bugs” technology has been shown to be well-tolerated in human tissues in vitro, and in multiple animal studies, are shelf-stable and do not require a cold-chain.
The compounds imitate key components of the immune system, humanity’s greatest asset in fighting disease. Maxwell’s technology is protected by numerous granted and pending patents and is led by a world-class team of scientists, military veterans, and experienced life science executives.
Source: Maxwell Biosciences